Mydecine: Nature’s Medicine for Mental Health
Treating mental health problems and enhancing vitality
Mydecine Innovations is dedicated to developing and commercializing innovative solutions for treating mental health problems and enhancing vitality. Its world-renowned medical and scientific advisory board is building out a robust R&D pipeline of nature-sourced psychedelic-assisted therapeutics, novel compounds, therapy protocols, as well as unique delivery systems.
“If Mydecine and others get to the commercial stage, they have enormous multibillion-dollar markets with very little competition,” says Elemer Piros.
Mydecine has exclusive access to a full cGMP certified pharmaceutical manufacturing facility. Further, they have the ability to import/export, cultivate, extract/isolate, and analyze active mushroom compounds. This is also all with full government approval through Health Canada. Additionally, Mydecine operates out of a state-of-the-art mycology lab in Denver, CO. There, the focus is on genetic research for scaling commercial cultivation of rare (non-psychedelic) medicinal mushrooms.
Moreover, Johns Hopkins, NYU, Imperial College of London are running controlled studies and are on a 12 month look back. The data results show that 67 percent of the individuals with severe PTSD no longer show the indication or signs of the indication. It also showed that over 80 percent show a significant reduction in their PTSD symptoms.
“I think it’s undeniable that this is the largest potential advancement in any sort of mental health treatment,” says Director, CEO & Co-Founder, Joshua Bartch.
A Remarkable Team
The Scientific Advisory Board (“SAB”) is enviable in the field of mental health solutions. Its current members are world-renowned medical and scientific professionals drawn from within academic, research and development, military, and corporate environments.
The members are leaders in the field of PTSD, Mental Health including clinical practice, and advocacy. Each member has therefore made significant contributions to advancing the field and is committed to furthering Mydecine’s mission. The SAB continues to provide strategic guidance and direction for Mydecine’s clinical trials for PTSD, underpinned by pure data research, therapy, and scientific programs, advise on intellectual property. It also contributes commentary on Mydecine’s telehealth platform, Mindleap Health™.
For more information on Mydecine Innovations Group (NEO: MYCO, OTC: MYCOF) please click the request investor info button